Skip to main content

Bionano Genomics, Inc.

corporate_fare Company Profile

Bionano Genomics, Inc.

BNGO·NASDAQ·Industrial Applications And Services·CIK 0001411690

Bionano Genomics, Inc. provides genome analysis solutions that help researchers and clinicians find answers in biology and medicine. The company aims to transform how the world views the genome using optical genome mapping ("OGM") solutions, nucleic acid extraction and purification systems, diagnostic services, and software. Bionano Genomics offers OGM solutions for basic, translational, and clinical research, as well as bioprocessing. Its platform-agnostic software integrates next-generation sequencing ("NGS"), microarray, and OGM data to analyze, visualize, interpret, and report copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in a single view. The company also provides nucleic acid extraction and purification solutions using its proprietary isotachophoresis ("ITP") technology. Through its Bionano Laboratories business, it offers OGM-based diagnostic testing services. The company develops, manufactures, markets, and sells OGM systems, including the Saphyr® system and the Stratys system. These systems provide OGM data for ultra-sensitive and ultra-specific detection of all classes of structural variation ("SV"). They are used to identify structural changes in chromosomes (cytogenetics) and to accelerate research in genetic disease, cancer, and cell and gene therapy applications. The systems consist of an instrument, chip consumables, reagents, and software with data analysis and visualization tools. OGM has demonstrated superior performance compared to current cytogenetic methods like karyotyping, fluorescence in-situ hybridization ("FISH"), Southern blot, and chromosomal microarray ("CMA") for SV detection, and can identify structural changes in chromosomes not detectable by current commercial gene sequencing solutions. Bionano Genomics also develops, manufactures, markets, and sells the Ionic® Purification system, which delivers high-quality DNA in a more natural, native form with fewer contaminants than other isolation and purification solutions.

Bionano Genomics, Inc. (NASDAQ:BNGO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 22 items for BNGO at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Bionano's OGM Studies Double at Key Genetics Meeting, Signaling Growing Adoption
  • Bionano Genomics Discloses Going Concern Doubt Amid Preliminary Q4 & FY25 Results

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$28.51M
Net Income
-$26.39M
Diluted EPS
-$4.85
Op. Cash Flow
-$16.34M
Gross Profit
$13.19M
Operating Income
-$33.34M
Cash & Equivalents
$2.99M
Debt / Equity
0.00×
Net Margin
-92.6%
Shares Outstanding
10.74M sh
Source: 10-K · filed 2026-03-23 · accession 0001411690-26-000007
$0.83 +0.95% today
52-week range · as of 2026-11-10 $0.83 – $2.23
Market cap
$11.5M
Volume
251.8K (1.0× avg)
3-mo avg 246.7K
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BNGO - Filings & News (Page 2)

BNGO
Mar 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.09
Real-time Price: $0.830 info
Change: -$0.260 (-24%) info
Market Cap: $11.502M info
BNGO
Jan 12, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.58
Real-time Price: $0.830 info
Change: -$0.750 (-47%) info
Market Cap: $11.502M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets